



# METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE

A research from a group from Foundation for Biomedical Research of La Paz University Hospital and CIBER.

## The Need

Aneurysmal subarachnoid hemorrhage represents a serious medical emergency with high mortality and morbidity due to early rebleeding. Approximately 11% of these patients die before receiving medical attention and 40% die within 4 weeks after admission to hospital. Among survivors 30% have a considerable limitation for activities of daily living and often suffer from cardiac complications associated with an increased risk of short-term death. Tako-Tsubo cardiomyopathy (TTC) is the main cardio-dysfunction that occurs after neurological damage The prevalence in SAH 's patients is between 20% and 30%, with a higher prevalence in women. There is a medical need in predicting risk of TTC in early SAH stages in order to adapt accordingly their treatment and monitoring.

### The Solution

The technology provides an in vitro method able to predict, at day 0 with 100% efficiency, patients with a subarachnoid aneurysmal hemorrhage that will develop a complication of Tako-Tsubo cardiomyopathy and therefore should follow a preventive treatment and monitoring.

The solution is based in determining the combined level of two molecules or their mRNA in serum/ blood samples obtained from the patient at emergency arrival.

#### **Innovative Aspects**

This type of test would bring the opportunity to:

- 1. Early prediction of SAH complications into a TTC cardiomyopathy.
- 2. Rapid and easy identification of patients.
- 3. Preventive treatment and monitoring of these patients.
- 4. Reduction of severity effects and mortality.
- 5. Minimally invasive method from serum or blood samples
- The IVD can be easily implemented to be performed in health services' currently available devices.

#### Stage of Development:

The method is currently being validated by the group in a bigger cohort of patients arriving though emergency services at hospitals.



Blood Test by Nick Youngson CC BY-SA 3.0 Alpha Stock Images

#### **Intellectual Property:**

Priority P202130180 Spanish Patent 3th March 2021

#### Aims

Looking for companies to develop the IVD thought licence or collaboration agreements.



# **Contact details**

Centro de Investigación Biomédica en Red (CIBER) Cristina Broceño Corrales, PhD. cbroceno@ciberes.org https://www.ciberisciii.es/en




Image by: https://www.heartfoundation.org.nz/